Cisco is set to buy portfolio company memo-transcription software provider Voicea in a deal that would allow Alphabet, Microsoft, Salesforce and Workday to exit.

Park Place has purchased the network analytics software provider in a deal of undisclosed size that will enable Mitsubishi to exit.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Bayer will pay up to $600 for the 59.2% stake in engineered-cell therapy developer BlueRock Therapeutics it does now own, following a $225m round in 2016.

The orphan disease drug developer's latest round was led by Novo while Asahi Kasei and Chiesi Ventures also participated, taking its overall funding to $46m.

Motion-to-compel fines have been served to parties from Stanford University and Stanford-StartX Fund for blocking MedWhat's discovery request in the ongoing legal case.

Exiting investor Mahindra Partners contributed to an Intel Capital-led round that increased the industrial internet-of-things technology developer's total funding to $39m.

Mission Bay Capital has backed a series B round for orphan diseases drug developer Glycomine, which also attracted Novo, Asahi Kasei Pharma and Chiesi.

BlueDot, a disease containment technology spinout set up by St Michael’s Hospital and Mars Innovation, has secured series A capital.